Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

Rock-solid capital adequacy and high level of customer activity

DNB’s profit for the fourth quarter of 2020 was NOK 5 274 million, which is NOK 671 million lower than the corresponding period in 2019. However, high levels of activity and growth in the personal customer market and SME corporate customer market – as well as in the savings and capital markets – contributed to DNB emerging strengthened from the highly unusual year. Despite the fact that the economic climate is still affected by uncertainty relating to the coronavirus pandemic, the Norwegian economy has begun a gradual recovery that is expected to speed up as the vaccination programme

Ahlstrom-Munksjö Financial Statements Release 2020: STRONG RESULT IMPROVEMENT AND CASH FLOW

AHLSTROM-MUNKSJÖ OYJ FINANCIAL STATEMENTS RELEASE February 10, 2021 at 08:30 EET This release is a summary of Ahlstrom-Munksjö’s Financial Statements Release 2020. The complete report is attached to this release as a pdf-file. It is also available at www.ahlstrom-munksjo.com. HIGHLIGHTS DURING THE REPORTING PERIOD · Strong improvement in comparable EBITDA and increased margin, all business areas improved · Lower variable costs more than offset slightly lower selling prices, sales volumes increased · Net sales impacted by an adverse currency effect · Strong cash flow, and

Evolution: Year-end report 2020

Fourth quarter of 2020 (Q4 2019) · Operating revenues increased by 68% to EUR 177.7 million (106.0) · EBITDA adjusted for non-recurring items amounted to EUR 115.6 million (55,8), an increase with 107%, for a margin of 65,1% (52,7%) · Non-recurring acquisition and restructuring costs amounted to EUR 19.4 million · EBITDA including non-recurring items increased by 72% to EUR 96.2 million (55.8), corresponding to a margin of 54.2% (52.7) · Profit for the period amounted to EUR 80.6 million (46.8) · Earnings per share amounted to EUR 0.42 (0.26) Full-year 2020 (2019)

Raisio plc Financial Statements Bulletin 2020

Financial Statements Bulletin of Raisio plc, 10 February 2021, 8:30 a.m. Finnish timeTaking the driver’s seat on the market roller coaster FINANCIAL DEVELOPMENT IN BRIEF January–December 2020 · The Group’s net sales totalled EUR 233.6 (236.3) million, which signified a decrease of -1.2%. · Comparable EBIT was EUR 27.7 (27.3) million, accounting for 11.9 (11.5)% of net sales. EBIT increased 1.8% in relation to the comparison period. · EBIT was EUR 28.9 (27.3) million, which accounted for 12.4 (11.5)% of net sales. · The overall effect of currency conversions was EUR -2.

Vestas launches the V236-15.0 MW to set new industry benchmark and take next step towards leadership in offshore wind

News release from Vestas Wind Systems A/SAarhus, 10 FebruaryVestas is the global leader in onshore wind, however to continue to lead the expansion of wind energy into becoming the dominant energy source, it is crucial for Vestas to become a leader in offshore wind. This journey was launched with the full acquisition of our former offshore joint venture, and we are now taking another step forward along our offshore innovation pathway by introducing the V236-15.0 MW turbine. The new technology establishes a strong foundation for Vestas’ offshore leadership journey by elevating the

Storebrand ASA: Key information relating to the cash dividend to be paid

Dividend amount: 3.25 per shareDeclared currency: NOKLast day including right: 8 April 2021Ex-date: 9 April 2021Record date: 12 April 2021Payment date: from 20 April 2021Date of approval: 8 April 2021 This information is published in accordance with the requirements of the Continuing Obligations and is subject to the disclosure requirements according to Section 5-12 of the Norwegian Securities Trading Act. Lysaker, 10 February 2021 Contact: Head of IR Daniel Sundahl: daniel.sundahl@storebrand.no or

ICA exceeds its climate targets

In conducting its climate emissions data year-end closing for 2020, ICA reports that greenhouse gas emissions from its own operations have decreased by 76% compared with 2006 levels. ICA has thereby exceeded its target to reduce GHG emissions by at least 70%. During 2020 ICA also launched its new climate ambition, which aims to achieve net zero emissions and cut the climate impact of customers’ grocery purchases in half by 2030.Emissions have been reduced through major initiatives and improvements in the areas of energy, refrigerants, logistics and goods transports. ICA offsets all

Storebrand Livsforsikring AS: 4Q Interim report 2020

Storebrand Livsforsikring AS is a wholly owned subsidiary of the listed company Storebrand ASA. For information about the Storebrand Group's 4Q 2020 result and Balance sheet statement, please refer to the Storebrand Group 4Q 2020 interim report. Storebrand Livsforsikring AS Group's interim report for 4Q 2020 is attached.   This information is subject of the disclosure requirements acc. to §5-12 vphl (Norwegian Securities Trading Act)

Elkem ASA – Key information relating to the proposed cash dividend

Oslo, 10 February 2021 Dividend amount:  NOK 0.15 per shareDeclared currency:  NOKDate of approval  27 April 2021Last day including right:  27 April 2021Ex-dividend date:  28 April 2021Record date:              29 April 2021Payment date:      On or about 6 May 2021 This information is subject to the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act.  For more information: Odd-Geir Lyngstad, VP Finance & Investor RelationsTel: +47 976 72 806Email: odd-geir.lyngstad@elkem.no

Panoro Energy ASA - Key information regarding potential subsequent offering

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART DIRECTLY OR INDIRECTLY, IN OR INTO AUSTRALIA, CANADA, JAPAN OR THE UNITED STATES OR ANY OTHER JURISDICTION IN WHICH THE RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL. THIS ANNOUNCEMENT DOES NOT CONSTITUTE AN OFFER TO BUY OR SUBSCRIBE OF ANY OF THE SECURITIES DESCRIBED HEREIN. Oslo, 10 February 2021 Reference is made to the stock exchange release by Panoro Energy ASA (the “Company” or "Panoro", with OSE Ticker: “PEN”) earlier today regarding the successful completion of a private placement of 38,276,451 new

Invitation to telephone conference in connection with Green Landscaping Group Year-end report 2020

Green Landscaping Group publishes its Year-end report on 17 February at 07:00 CET.CEO Johan Nordström and CFO Carl-Fredrik Meijer will present the report and answer questions during a telephone conference with a web presentation on17 February at 10:30.Participants dial in: Telephone: +46 8 566 426 51PIN code: 24058480# Webcast: https://edge.media-server.com/mmc/p/iqoymo4s The presentation will be held in English.

Record sales and highest earnings since 2018

The result for the fourth quarter 2020 was Elkem’s best since 2018. The high earnings reflect Elkem’s robust business model with strong market positions and favourable cost positions. This has enabled Elkem to keep close to full production through the Covid-19 pandemic so far and now capitalise on the improved market conditions during the quarter to reach record sales. Elkem’s total operating income for the fourth quarter 2020 was NOK 7,129 million, which was all-time high and up 28% from the corresponding quarter last year. Earnings before interest, taxes, depreciation and amortisation (

Niam chooses Netmore's turnkey 5G solution for rollout of open 5G infrastructure in its Nordic property portfolio

Niam, one of the largest private property owners in the Nordic region with over 1.7 million square meters of real estate in its portfolio, chooses Netmore as its 5G operator when they begin the implementation of open 5G infrastructure for indoor use in their properties. Netmore delivers a turnkey 5G solution without any need for CAPEX investments or operation and maintenance work for the property owner (5G-as-a-service). The solution enables property owners to use the technology themselves, while mobile operators can use the infrastructure and offer 5G services at the location. By doing so,

Targovax and Papyrus Therapeutics enter research collaboration to develop novel ONCOS viruses with receptor tyrosine kinase (RTK) inhibitor functionality

· The parties will explore the feasibility and effect of combining their respective oncolytic virus and receptor tyrosine kinase (RTK) inhibitor technologies · Targovax retains the right to develop and commercialize novel drug candidates emerging from the pre-clinical collaboration Oslo, Norway 10 February 2021 – Targovax ASA (OSE: TRVX), a clinical stage immuno-oncology company developing immune activators to target hard-to-treat solid tumors, today announces that it has entered into a research collaboration agreement with Papyrus Therapeutics to assess the potential of combining

STOREBRAND ASA: Results for the 4th Quarter 2020

Leading the Way in Sustainable Value Creation – Strongest Quarter on Record· Group profit[1] of NOK 1,225m in the 4th quarter, strongest on record · Solvency II ratio 178% · Proposed dividend of NOK 3.25 per share · Total Assets under Management (AuM): NOK 962bn, 16% growth y/y – The Storebrand Group delivers its strongest quarter on record, driven by continued growth in assets under management and insurance premiums. The Group's profit grew by 19 per cent to NOK 1,225 million in the fourth quarter, compared to last year. Underlying growth within the core business Savings and

ICA Gruppen Year-end report 2020

Strong close to the year with continued pandemic impactsFourth quarter 2020 · Consolidated net sales increased by 5.6% to SEK 32,593 million (30,850) · Operating profit excluding items affecting comparability increased to SEK 1,371 million (1,267). Overall, non-recurring items in operating profit are considered to be insignificant. In operating profit for 2019, these were calculated at SEK -50 million net. · Consolidated sales and operating profit were affected by the continuing Covid-19 pandemic, where ICA Sweden and ICA Real Estate benefited, while other segments were

BERGENBIO ASA: RESULTS FOR THE FOURTH QUARTER AND FULL YEAR 2020

Bergen, Norway, 10 February 2021 – BerGenBio ASA (OSE:BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical need, announces its results for the fourth quarter and full year 2020. A presentation and live webcast by BerGenBio’s senior management will take place at 10.00 am CET today, please see below for details. Operational Highlights – fourth quarter (including post-period end)  · First patient enrolled in South Africa and India as part of Company sponsored randomised Phase II trial assessing bemcentinib as a

Panoro Energy – US$ 70 Million Oversubscribed Private Placement Successfully Completed – Mandatory notification of trades

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART DIRECTLY OR INDIRECTLY, IN AUSTRALIA, CANADA, JAPAN OR THE UNITED STATES OR ANY OTHER JURISDICTION IN WHICH THE RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL. THIS ANNOUNCEMENT DOES NOT CONSTITUTE AN OFFER OF ANY OF THE SECURITIES DESCRIBED HEREIN. Oslo, 10 February 2021 Reference is made to the stock exchange release by Panoro Energy ASA (the “Company” or “Panoro”, with OSE Ticker: “PEN”) on 9 February 2021 regarding a contemplated private placement (the “Private Placement”) of new shares in the Company with

Kristofer Liljeberg appointed new Head of Research at Carnegie

Kristofer Liljeberg, one of the most experienced and highly regarded equity analysts in Sweden, is the new Head of Swedish Research at Carnegie. Mr Liljeberg has been with Carnegie for 25 years, where his principal focus has been healthcare sector research.“Research is a cornerstone of all Carnegie advisory. Our ambition is to maintain the broadest research coverage of Nordic companies with no ‘sponsored research’. In line with our plans to further expand the number of companies we cover, we have recently carried out several recruitments across a range of sectors,” says Liljeberg.

Deep seabed mining is an avoidable environmental disaster

New report, “In Too Deep: What We Know, And Don’t Know, About Deep Seabed Mining,” outlines likely impacts of deep seabed mining on ecosystems and biodiversity, and risks of allowing industry to proceed.Lisbon, 10 February 2021 – The investigation “In Too Deep: What We Know, And Don’t Know, About Deep Seabed Mining”, released today by WWF, argues that there are many unknowns and much to do in ocean science, policy and industry innovations before any deep seabed mining activities should be allowed to take place.WWF says industry plans to mine the deep seabed for metals and minerals such as

Notice of extraordinary general meeting of Vicore Pharma Holding AB (publ)

The shareholders of Vicore Pharma Holding AB (publ), Reg. No. 556680-3804, with registered office in Gothenburg, are summoned to the extraordinary general meeting Friday 5 March 2021.The continued spread of COVID-19 remains difficult to assess with any certainty. Due to the prevailing extraordinary situation, Vicore Pharma’ s extraordinary general meeting will be held in a different way than usually. Vicore Pharma is mindful of the health of the shareholders as well as the work to limit the spread of the virus. Thus, in order to reduce the risk of spreading the virus and having regard to

Vicore Pharma has completed a directed share issue of SEK 336 million

NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, WITHIN OR TO THE UNITED STATES, AUSTRALIA, CANADA, HONG KONG, JAPAN, NEW ZEALAND, SINGAPORE, SOUTH AFRICA, SWITZERLAND OR IN ANY OTHER JURISDICTION WHERE THE RELEASE, DISTRIBUTION OR PUBLICATION OF THIS PRESS RELEASE WOULD BE UNLAWFUL OR WOULD REQUIRE REGISTRATION OR ANY OTHER MEASURESGothenburg, February 10, 2021 – Vicore Pharma Holding AB (publ) (“Vicore Pharma” or the “Company”), announces, as indicated in the Company’s press release earlier today, that the Company has successfully completed a

There are no items matching the current filter
There are no more items matching the current filter
Back to top